Ocular absorption following topical delivery

Advanced Drug Delivery Reviews

Volumn 16, Issue 1, 1995, Pages 3-19

  Järvinen, Kristiina ^a   Järvinen, Tomi ^a   Urtti, Arto ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Corneal permeability; Cyclodextrin; Drug delivery; Ocular absorption; Ocular pharmacokinetics; Ophthalmic drug

Indexed keywords

ABSORPTION; COMPOSITION EFFECTS; DISEASES; DRUG PRODUCTS; HEMODYNAMICS; MECHANICAL PERMEABILITY; OPHTHALMOLOGY; PHARMACOKINETICS; VISION;

CORNEAL PERMEABILITY; CYCLODEXTRIN; OCULAR ABSORPTION; OCULAR PHARMACOKINETICS;

CONTROLLED DRUG DELIVERY;

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 5 (3 DIMETHYLAMINOMETHYL 4 HYDROXYPHENYLSULFONYL) 2 THIOPHENESULFONAMIDE; ADRENALIN; AHR 16329; APRACLONIDINE; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CARBONATE DEHYDRATASE INHIBITOR; CEFAZOLIN; CYCLODEXTRIN; DIMETHYL BETA CYCLODEXTRIN; EYE DROPS; FOSCARNET; GANCICLOVIR; GELRITE; GENTAMICIN; LEVOBUNOLOL; MACROGOL; MANNITOL; PILOCARPINE; POLYCAPROLACTONE; POLYMER; SEZOLAMIDE; TICARCILLIN; TIMOLOL; TROPICAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AQUEOUS HUMOR; CONJUNCTIVA; CORNEA; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG ELIMINATION; EYE; EYE DISEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCLERA; TOPICAL DRUG ADMINISTRATION; UVEA;

EID: 0029347459     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00010-5     Document Type: Review

References (170)

1. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits
2. Ocular pharmacokinetics
3. Ocular drug delivery. Pharmacokinetic considerations
4. Importance of the noncorneal absorption route in topical ophthalmic drug delivery
5. Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption
6. ®: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effects of bioavailability of timolol
7. Relative bioavailability of pilocarpine from a novel ophthalmic delivery system and conventional eyedrop formulations
8. Minimizing systemic absorption of topically administered ophthalmic drugs
9. Systemic absorption of ocular pilocarpine is modified by polymer matrices
10. Evaluation of timolol maleate combination therapy in chronic open-angle glaucoma
11. Combined timolol and pilocarpine vs pilocarpine alone and timolol alone in the treatment of glaucoma
12. Additive effect of epinephrine to timolol therapy in primary open angle glaucoma
13. Timolol and epinephrine. Long-term evaluation of concurrent administration
14. Safety and effectiveness of concomitant administration of dipivefrin and timolol maleate
15. Comparison of two treatment schedules for combined timolol and dipivefrin therapy
16. Is it worthwhile to add dipivefrin HCl 0.1% to topical β1-, β2-blocker therapy?
17. Timolol-pilocarpine combined vs timolol and pilocarpine given separately
18. Ophthalmic epinephrine, phenylephrine, and pilocarpine affect the systemic absorption of ocularly applied timolol
19. Pharmacokinetic basis of nonadditivity of intraocular pressure lowering timolol combinations
20. Ocular drug interactions involving topically applied timolol in pigmented rabbits
21. Effects of epinephrine pretreatment and solution pH on ocular and systemic absorption of ocularly applied timolol in rabbits
22. Ophthalmic drug delivery systems
23. Treatment of diseases of the eye with mucoadhesive delivery systems
24. Review: Topical ocular drug delivery: recent developments and future challenges
25. Mechanisms and facilitation of corneal drug penetration
26. Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit
27. Drop size of commercial glaucoma medications
28. A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man
29. Lacrimal and instilled fluid dynamics in rabbit eye
30. The evaluation of viscous ophthalmic vehicles by slit lamp fluorophotometry in humans
31. Evaluation of viscous ophthalmic vehicles containing carbomer by slit-lamp fluorophotometry in humans
32. Gamma scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various ophthalmic formulations containing pilocarpine
33. Limits on optimizing ocular drug delivery
34. The pharmacology of antiglaucoma drugs
35. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea
36. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration
37. Role of enzymatic lability in the corneal and conjunctival penetration of timolol ester prodrugs in the pigmented rabbit
38. Comparison of conjunctival and corneal surface areas in rabbit and human
39. Design and evaluation of controlled release systems for the eye
40. Epithelial and corneal thickness measurements by high-frequency ultrasound digital signal processing
41. Interferometric measurement of corneal thickness with micrometer precision
42. Mechanisms of corneal drug penetration II: Ultrastructural analysis of potential pathways for drug movement
43. Intestinal permeability of ophthalmic β-blockers for predicting ocular permeability
44. Topographical differences in cell area at the surface of the corneal epithelium of the pigmented rabbit
45. Confocal laser scanning microscopic examination of transport pathways and barriers of some peptides across the cornea
46. Permeability of horseradish peroxidase in the rabbit corneal epithelium
47. Ontogeny of corneal epithelial tight junctions: Stratal locale of biosynthetic activities
48. Rabbit corneal epithelial wound repair: tight junction reformation
49. Rate limiting barrier to the penetration of ocular hypotensive beta blockers across the corneal epithelium in the pigmented rabbit
50. Structure biochemistry and assembly of epithelial tight junctions
51. Identification of ZO-1: A high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia
52. Cingulin, a new peripheral component of tight junctions
53. Identification of a 160-kDa polypeptide that binds to the tight junction protein ZO-1
54. Occludin: a novel integral membrane protein localizing at tight junctions
55. The cytoskeleton of the cornea and its role in tight junction permeability
56. Regulation of tight junction permeability by calcium mediators and cell cytoskeleton in rabbit tracheal epithelium
57. Effects of calcium chelating agents on corneal permeability
58. Structure of tight junctions in epithelia with different permeability
59. The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit
60. The effect of polyethylene glycol molecular weight on corneal transport and the related influence of penetration enhancers
61. Paracellular permeability of corneal and conjunctival epithelia
62. The three-dimensional organization of collagen fibrils in the human cornea and sclera
63. The network structure of corneal fibroblasts in the rat as revealed by scanning electron microscopy
64. The developing corneal endothelium: correlation of morphology, hydration and Na/K ATPase pump site density
65. Recent studies on the nature and function of the corneal endothelial barrier
66. Ocular penetration enhancers
67. Assessment of transport barriers using cell and tissue culture systems
68. The effect of drug charge type and charge density on corneal transport
69. Study of the mechanism of interaction of poly(ε-caprolactone) nanocapsules with the cornea by confocal laser scaning microscopy
70. Corneal penetration behaviour of β-blocking agents I: physicochemical factors
71. Vehicle effects on ocular drug bioavailability II: Evaluation of pilocarpine
72. Ocular pharmacology of sulfonamides: the cornea as barrier and depot
73. pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors
74. Prodrug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit
75. Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients
76. Theoretical corneal permeation model for ionizable drugs
77. Age-related differences in ophthalmic drug disposition. III. Corneal permeability of pilocarpine in rabbits
78. Mechanism of transcorneal permeation of pilocarpine
79. The effect of a modified β-cyclodextrin, SBE4-β-CD, on the aqueous stability and ocular absorption of pilocarpine
80. Transport mechanisms of the cornea: characterization of barrier permselectivity
81. Metabolic and permeation barriers to the ocular absorption of topically applied enkephalins in albino rabbits
82. Routes of delivery: case studies. (7) Ocular delivery of peptide and protein drugs
83. Aminopeptidase activity in homogenates of various absorptive mucosae in the albino rabbit: implications in peptide delivery
84. Ocular iontophoresis
85. Ion channels in ocular epithelia
86. Anion channels in the apical membrane of mammalian corneal epithelium primary cultures
87. Single potassium channels in corneal epithelium
88. Transport processes across the rabbit corneal epithelium: a review
89. Mechanism of chloride uptake in rabbit cornal epithelium
90. Effects of calcium channel blockers on rabbit corneal endothelial function
91. Stromal acidosis modulates corneal swelling
92. + adenosine triphosphatase in corneal epithelium
93. Cultured bovine corneal endothelial cells express CHIP28 water channels
94. + ATPase in cultured corneal endothelial and epithelial cells
95. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes
96. Molecular weight dependence of PEG permeability in cornea, conjunctiva and sclera in vitro
97. Modification of rabbit conjunctiva following instillation of commonly used ophthalmic drugs
98. In vitro growth and differentiation of rabbit bulbar, fornix, and palpebral conjunctival epithelia
99. Expression of keratins K12, K4 and K14 during development of ocular surface epithelium
100. Conjunctival epithelial cells do not transdifferentiate in organotypic cultures expression of K12 keratin is restricted to corneal epithelium
101. Conjunctival penetration of insulin and peptide drugs in the albino rabbit
102. Evaluation of permeablity enhancement of hydrophlic compounds and macromolecular compounds by bile salts through rabbit corneas in-vitro
103. Electrical potential and ion transport across the conjunctiva
104. Active chloride transport in the pigmented rabbit conjunctiva
105. Collagens in the aged human macula sclera
106. Corneal and scleral penetration studies of 6-hydroxyethoxy-2-benzothiazole sulfonamide: a topical carbonic anhydrase inhibitor
107. Intravitreal delivery of ganciclovir in rabbits by transscleral iontophoresis
108. Transscleral iontophoresis of foscarnet
109. Transscleral iontophoresis of cefazolin, ticarcillin, and gentamicin in the rabbit
110. Experimental transscleral iontophoresis of ciprofloxacin
111. Effects of eyelid closure and nasolacrimal duct occlusion on the systemic absorption of ocular timolol in human subjects
112. The effect of reduced eyedrop size and eyelid closure on the therapeutic index of phenylephrine
113. Effect of nasolacrimal occlusion on timolol concentrations in the aqueous humor of the human eye
114. Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion
115. Improving the safety of topically applied timolol in the pigmented rabbit through manipulation of formulation composition
116. Bioadhesion: the effect of polyacrylic acid on the ocular bioavailability of timolol
117. Improved ocularsystemic absorption ratio of timolol by viscous vehicle and phenylephrine
118. Sodium acetate improves the ocular/systemic absorption ratio of timolol applied ocularly in monoisopropyl PVM/MA matrices
119. Modification of ocular and systemic absorption of timolol from ocular inserts by a buffering agent and a vasoconstrictor
120. Controlled drug delivery devices for experimental ocular studies with timolol. 2. Ocular and systemic absorption in rabbits
121. Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans
122. Poly(ε-caprolactone) nanocapsules in carteolol ophthalmic delivery
123. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol
124. Prodrugs for improved ocular drug delivery
125. Drug design strategies for ocular therapeutics
126. Influence of ion pairing salts on the transcorneal permeability of ionized sulfonamides
127. Altered ocular absorption and disposition of sodium cromoglycate upon ion-pair and complex coacervate formation with dodecylbenzyldimethylammonium chloride
128. Formulation influence on ocular and systemic absorption of topically applied atenolol in the pigmented rabbit
129. Optimizing the systemic and ocular absorption of timolol from eye drops
130. Novel ‘soft’ betablockers as potential safe antiglaucoma agents
131. Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation
132. Delivery of antiglaucoma drugs: ocular vs. systemic absorption
133. The use of liposomes as drug carriers in ophthalmology
134. Comparative dissolution characteristics of bropirimine-β-cyclodextrin inclusion complex and its solid dispersion with PEG 6000
135. Effect of various cyclodextrins on solution stability and dissolution rate of doxorubicin hydrochloride
136. The effect of 2-hydroxypropyl-β-cyclodextrin on the simultaneous dissolution and degradation of chlorambucil
137. Study of the dissolution characteristics of oxazepam via complexation with β-cyclodextrin
138. Effect of cyclodextrin derivatives on indometacin stability in aqueous solution
139. Kinetics of aspirin hydrolysis and stabilization in the presence of 2-hydroxypropyl-β-cyclodextrin
140. The effect of cyclodextrin on the solubility and stability of medroxyprogesterone acetate and megestrol acetate in aqueous solution
141. Effect of 2-hydroxypropyl-β-cyclodextrin on the stability of prostaglandin E2 in solution
142. Solubilization and stabilization of a benzylpenicillin chemical delivery system by 2-hydroxypropyl-β-cyclodextrin
143. Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex
144. Improvement of oral bioavailability of carbamazepine by inclusion in 2-hydroxypropyl-β-cyclodextrin
145. Inclusion mode of fluriboprofen with β-cyclodextrin and heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin, and improvements of some pharmaceutical properties of fluribiprofen by complexation
146. Improvement of dissolution and absorption characteristics of phenytoin by water-soluble β-cyclodextrin-epichlorohydrin polymer
147. Moderation of untoward side effects during in vivo and in vitro screening of potential intravenous preparations
148. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam beta-cyclodextrin, piroxicam and placebo administration
149. Cyclodextrins in pharmaceutical field
150. Medical applications of cyclodextrins
151. Cyclodextrins, properties and applications
152. Beta-cyclodextrins as vehicles in eye-drop formulations: An evaluation of their effects on rabbit corneal epithelium
153. Ocular absorption and irritation of pilocarpine prodrug is modified with buffer polymer and cyclodextrin in the eyedrop
154. Sulfobutyl ether β-cyclodextrin (SBE-β-CD) in eyedrops improves the tolerability of a topically applied pilocapine prodrug in rabbits
155. Beta-cyclodextrins enhance bioavailability of pilocarpine
156. In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to the commercial product Voltaren ophtha
157. The effects of cyclodextrins on drug absorption. II. In vivo observation
158. Effect of the interaction of drug-β-cyclodextrin complex with bile salts on the drug absorption from rat small intestinal lumen
159. Influenfe of β-cyclodextrin on intra-ocular concentrations of the topical carbonic anhydrase inhibitor, L-671,152, in rabbits
160. Ocular pharmacokinetics/pharmacodynamics
161. The effect of hydroxypropyl methylcellulose of the release of dexamethasone from aqueous 2-hydroxypropyl-β-cyclodextrin formulations
162. The effect of 2-hydroxypropyl-β-cyclodextrin on ocular absorption of dexamethasone and dexamethasone acetate
163. 2-Hydroxypropyl-β-cyclodextrin in topical carbonic anhydrase inhibitor formulations
164. Influence of vehicle and anterior chamber protein concentration on cyclosporine penetration through the isolated rabbit cornea
165. Disposition of ophthalmic timolol in treated and untreated rabbit eyes. A multiple and single dose study